Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dacomitinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 8/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | SRC | P12931 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | MC3R | P41968 | 1/20 | 0.98 |
| ▸ | JAK3 | P52333 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacomitinib Anhydrous SCHEMBL22498351 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29359689 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29445648 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL33136 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29377735 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL25098 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL33147 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL30115337 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29354322 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325543-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | ASTRAZENECA AB (SE) | 2025-10-23 | — | — | US | disclosed |
| EP-4543920-A1 | COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4499102-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-02-05 | — | — | EP | disclosed |
| CN-119278041-A | Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors in combination with AKT inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240423978-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| WO-2024002938-A1 | COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-01-04 | — | — | WO | disclosed |
| EP-4259146-A1 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A EGFR-INHIBITOR FOR TREATING SOLID TUMORS | Genentech, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023187037-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | WO | disclosed |
| EP-4157267-A1 | EGFR TKIS FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Astrazeneca AB (SE) | 2023-04-05 | — | — | EP | disclosed |
| CN-115776889-A | EGFR TKI for treatment of non-small cell lung cancer | 阿斯利康(瑞典)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4093394-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| CN-112661707-B | Preparation method of dacomitinib | 扬子江药业集团有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114980883-A | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022125427-A1 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A EGFR-INHIBITOR FOR TREATING SOLID TUMORS | GENENTECH, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3946346-A1 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423978-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB4 3/4885 |
| US-20250325543-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.